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The morbidity and mortality of colon cancer are still very high, although medical technology has greatly 
improved in recent years. This study explored the role of miR-142a-5p in the proliferation of colon cancer cells. 
The binding between miR-142a-5p and PLK1 was verified by using luciferase assays. Western blotting was 
employed to determine whether PLK1 is the direct target gene of miR-142a-5p. In addition, a Cell Counting Kit-
8 (CCK-8) assay was used to determine whether miR-142a-5p inhibited the proliferation of colon cancer cells by 
targeting PLK1. Our results show the clear binding between miR-142a-5p and PLK1. Reduced PLK1 expression 
in colon cancer cells transfected a miR-142a-5p mimic and increased PLK1 expression in colon cancer cells 
transfected with a miR-142a-5p inhibitor were observed. Moreover, the overexpression of PLK1 promoted cell 
proliferation, while the miR-142a-5p mimic inhibited cell proliferation. In conclusion, our findings indicate that 
miR-142a-5p inhibits the proliferation of colon cancer cells by downregulating PLK1. 
Keywords: colon cancer; cell proliferation; miR-142a-5p; PLK1; tumor 
To cite this article: Ruan Zhibing, et al. Colon cancer cell proliferation is inhibited by miR-142a-5p via regulation of the 
PLK1 gene. RNA Dis 2019; 6: e448. doi: 10.14800/rd.448. 
 
Colon cancer is one of the most common malignant tumors 
in the world, and its morbidity and mortality are very high [1]. 
In recent years, with the advancement of medical technology, 
the survival of colon cancer patients has improved, but the 
incidence of colon cancer is still high [2]. Most patients are 
diagnosed at the middle to late stages and miss the best period 
for treatment [3]. Defining the exact molecular mechanisms of 
colon cancer development and progression is critical for the 
diagnosis and treatment of colon cancer. 
Polo-like kinase 1 (PLK1) is a class of highly conserved 
serine/threonine kinases that are highly regulated in 
eukaryotic cells and play a very important regulatory role in 
the cell cycle [4]. It has been reported that PLK1 is highly 
expressed in various cancers (such as colon cancer, non-small 
cell lung cancer, breast cancer, esophageal cancer, and 
endometrial cancer), and it acts as an oncogenic protein to 
promote the development of cancer [5-9]. In leukemia cells, 
the knockdown of PLK1 with a small interfering RNA can 
significantly inhibit the proliferation of leukemia cells [10]. In 
colon cancer, high PLK1 expression may promote the 
metastasis of tumor cells, and PLK1 may be one of the target 
proteins for colon cancer treatment [11]. 
MicroRNAs (miRNAs) are a class of noncoding RNAs that 
are 19-22 nucleotides in length and play an important 
regulatory role in the development and progression of cancer 
[12]. Studies have shown that miRNAs may directly bind to 
the coding sequence of a mRNA or bind to the 3'-untranslated 
region (UTR) of the target gene mRNA to inhibit gene  
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Figure 1. PLK1 promotes the proliferation of colon cancer 
cells. PLK1 protein expression is increased in cells 
transfected with the PLK1 plasmid compared to cells 
transfected with the control plasmid (*P <0.05). In contrast, 
PLK1 protein expression is reduced in cells transfected with 
the PLK1 siRNA compared to cells transfected with the 
control siRNA (**P <0.05) (A and B). The proliferation of 
colon cancer cells transfected with the PLK1 overexpression 
plasmid is promoted compared to cells transfected with the 
control plasmid (*P <0.05) but inhibited compared to cells 
transfected with the PLK1 siRNA (**P <0.05) (C). 
 
expression [13-14]. miRNAs, as important posttranscriptional 
regulators, are involved in many physiological and 
pathological processes, such as hematopoietic cell 
differentiation [15], cell proliferation [16], organ development 
[17] and tumorigenesis [18-19]. miRNAs can function as 
tumor suppressor miRNAs or cancer-promoting miRNAs in 
the development of tumors [20], and many miRNAs are also 
involved in the development of colon cancer [21]. Studies 
have shown that miR-142a-5p plays important roles in the 
pathophysiology of many diseases, such as hyperlipidemia [22] 
and myocardial infarction [23], but little is known regarding 
miR-142a-5p in colon cancer. In this study, we investigated 
the effects and regulatory mechanisms of miR-142a-5p on 
colon cancer proliferation. 
Materials and methods 
Colon cancer cell lines 
Human colon cancer cell lines SW480 and HCT116 were 
purchased from the Shanghai Cell Bank of the Chinese 
Academy of Sciences. SW480 and HCT116 cells were 
cultured in 5% CO2 at 37 °C and in complete DMEM 
(HyClone) supplemented with antibiotics (100 U/mL 
penicillin and 100 mg/L streptomycin) and 10% fetal bovine 
serum (HyClone). The cells were used for subsequent 
experiments after reaching the logarithmic growth phase. 
miR-142a-5p transfection 
The miR-142a-5p mimic and the miR-142a-5p inhibitor 
were purchased from Guangzhou Ruibo Biological Co., Ltd. 
Cell transfection experiments were performed with 
Lipofectamine 3000 reagent (Invitrogen) according to the 
manufacturer’s instructions. A small interfering RNA (siRNA) 
targeting PLK1 was purchased from Guangzhou Ruibo 
Biotechnology Co., Ltd., and a PLK1 overexpression plasmid 
(including the open reading frame only) was purchased from 
Shanghai Jima Biotechnology Co., Ltd. Cell transfection 
experiments were performed with Lipofectamine 3000 reagent 
according to the manufacturer’s instructions. 
Detection of PLK1 expression 
After transfection for 24 h, the cell lysates of the transfected 
group were collected and centrifuged at 12,000 g at 5 °C for 5 
min, and the supernatant was aspirated. Next, 5× protein 
loading buffer was added and incubated at 100 °C for 5 min. 
After electrophoresis by SDS-PAGE (10%), the membrane 
was transferred (ice bath, 0.3 A, 1.5 h) and blocked (5% skim  
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Figure 2. Prediction and dual luciferase reporter plasmid assay to confirm the 
binding of miR-142a-5p with the PLK1 gene. TargetScan was used to predict 
whether miR-142a-5p has a binding site for the 3'-UTR of PLK1 (A); Luciferase 
reporter assay shows that the fluorescence value of the 3'-UTR of the PLK1 gene 
was significantly decreased after adding the miR-142a-5p mimic (*P < 0.05), while 
after the sequence mutation and transfection with the miR-142a-5p mimic, the 
fluorescence value was not significantly different from that of the control group 
(**P > 0.05). 
 
milk powder, room temperature for 1 h). Then, a PLK1 I 
antibody (ABclonal; diluted 1:1000) was added and incubated 
overnight at 4 °C. The membrane was washed with TBST for 
5 min for a total of 6 times. The diluted secondary antibody 
was added and incubated for 1 h at room temperature. The 
membrane was washed with TBST for 5 min for a total of 6 
times. GAPDH (Abcam) was used as the control. 
Cell viability detection 
The number of cells at 4 time points (0, 24, 48, and 72 h) 
after transfection was determined using the Cell Counting Kit-
8 (CCK-8) kit (Japan Tongren) according to the 
manufacturer’s instructions. The absorbance at 450 nm was 
monitored using a microplate reader. All experiments were 
repeated three times. 
Luciferase assay 
The dual luciferase reporter gene was used to detect whether 
miR-142a-5p directly targets the PLK1 gene. The 3'-UTRs for 
the wild-type and mutant PLK1 luciferase reporter plasmids 
were synthesized by Shanghai Tongke Biotechnology Co., 
Ltd., and the sequence of the 3'-UTR of PLK1 was inserted 
into the pmirGLO vector (Promega, E1330) to form the PLK1 
3'-UTR plasmid. An equal amount of the luciferase reporter 
plasmid described above and a β-galactosidase (β-gal) 
expression plasmid (Ambion) and 20 pmol of the miR-142a-
5p mimic or control were transfected into colon cancer cells 
with Lipofectamine 3000 reagent. The β-gal plasmid was used 
as a control to determine transfection efficiency. After 24 h, 
cells were detected using a luciferase assay kit. 
Statistics 
SPSS 22.0 software was utilized to perform the data 
analysis. The data are expressed as the mean ± standard 
deviation (SD). One-way analysis of variance was used for 
comparison between groups. P < 0.05 was considered 
statistically significant. 
Results 
PLK1 promotes the proliferation of colon cancer cells 
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Figure 3. PLK1 expression is regulated by miR-142a-5p in colon cancer cells. The expression of the PLK1 protein was 
decreased in the miR-142a-5p-overexpressing cell lines compared to that in the control group (A-D). After inhibiting the 
expression of miR-142a-5p by transfection with the miR-142a-5p inhibitor, the expression of the PLK1 protein was 
significantly increased compared to that in the control group (A-D). *P < 0.05; **P < 0.05. 
 
The PLK1 overexpression plasmid and the siRNA were 
transfected into cells for 24 h, and cell proliferation was 
assessed with the CCK-8 kit. PLK1 expression was increased 
significantly in cells transfected with the PLK1 
overexpression plasmid when compared to cells transfected 
with the control plasmid (Figure 1A and B). However, PLK1 
expression was reduced significantly in cells transfected with 
the PLK1 siRNA when compared to cells transfected with the 
control plasmid (Figure 1A and B). In addition, the 
proliferation of colon cancer cells transfected with the PLK1 
overexpression plasmid was promoted significantly compared 
to cells transfected with the control siRNA (Figure 1C). In 
contrast, proliferation was reduced in cells transfected with the 
PLK1 siRNA when compared to cells transfected with the 
control siRNA, which suggests that PLK1 is involved in the 
proliferation of colon cancer cells (Figure 1C). 
Prediction and validation of PLK1 as a target gene of miR-
142a-5p 
This study used TargetScan [24-26] to find miRNAs that 
may bind to PLK1. Among these candidates, miR-142a-5p 
was predicted by TargetScan as a PLK1-bound miRNA. miR-
142a-5p has a binding site for the 3'-UTR of PLK1 (Figure 
2A). In addition, the region where the 3'-UTR of PLK1 binds 
complementarily to the miR-142a-5p sequence is highly 
conserved between species. To verify the above prediction, 
this study conducted a dual luciferase reporter gene assay 
(Figure 2B). The fluorescence value of the 3'-UTR of the 
PLK1 gene was significantly decreased after adding the miR-
142a-5p mimic (*P < 0.05). However, after the sequence 
mutation and transfection with the miR-142a-5p mimic, the 
fluorescence value was not significantly different from that of 
the control group (**P > 0.05). 
miR-142a-5p regulates the expression of PLK1 in colon 
cancer cells 
To further demonstrate the effect of miR-142a-5p on PLK1 
expression, a miR-142a-5p mimic and a miR-142a-5p 
RNA & DISEASE 2019; 6: e448. doi: 10.14800/rd.448; ©  2019 by Ruan Zhibing, et al. 
http://www.smartscitech.com/index.php/rd 
 
Page 5 of 6 
 
inhibitor were transfected into two colon cancer cells and 
detected by Western blot 24 h later. After the overexpression 
of miR-142a-5p in both cell lines, the expression level of the 
PLK1 protein was decreased compared to that in the control 
group. After inhibiting the expression of miR-142a-5p by 
transfection with a miR-142a-5p inhibitor, the expression 
level of the PLK1 protein was significantly increased (Figure 
3A, B). 
miR-142a-5p inhibits the proliferation of colon cancer cells 
After transfecting colon cancer cells with the miR-142a-5p 
mimic and the miR-142a-5p inhibitor for 24 h, cell 
proliferation ability was assessed with the CCK-8 kit. After 
the overexpression of miR-142a-5p, cell proliferation was 
significantly inhibited (P < 0.05, Figure 4). However, when 
miR-142a-5p was inhibited by transfection with the miR-
142a-5p inhibitor, cell proliferation was significantly higher 
than that of the control group (P < 0.05, Figure 4). 
 
Figure 4. miR-142a-5p inhibits the proliferation of colon cancer cells. 
The proliferation of colon cancer cells transfected with the miR-142a-5p 
mimic is reduced while the proliferation of cells transfected with the 
miR-142a-5p inhibitor is increased compared to the corresponding 
control group (*P < 0.05). 
 
Discussion 
As important posttranscriptional regulators, miRNAs play 
an important role in the development of tumors [27]. Existing 
studies have shown that miRNAs have both inhibitory and 
stimulatory effects on the development of colon cancer [28]. 
Studies have shown that miR-593 affects the proliferation of 
colon cancer by regulating the expression of the PLK1 gene 
[29]. PLK1 was originally identified in Drosophila as a protein 
involved in spindle formation, and further studies indicated 
that this kinase plays a key role in centrosome biology, spindle 
dynamics, chromosome segregation, and cytokinesis [30]. 
Numerous studies have shown that the early stages of PLK1 
cancer development play a role, and its overexpression is 
negatively correlated with the survival rate of non-small cell 
lung cancer, head and neck cancer and esophageal cancer 
patients [31-32]. The use of small molecule inhibitors of PLK1 
to treat tumors such as leukemia and non-small cell lung 
cancer is currently a clinical treatment strategy [33]. However, 
in colon cancer, the regulation of the presence or absence of 
miRNAs in PLK1 has not been studied. 
To identify miRNAs that may regulate the expression of the 
PLK1 gene, the bioinformatics program TargetScan was used 
to predict whether miR-142a-5p might bind to PLK1 miRNA 
[26-28]. We found that PLK1 promoted the proliferation of 
colon cancer cells (as assessed by CCK-8 cell proliferation 
assays), which is consistent with the results of other studies 
[34], and after interfering with the expression of miR-142a-5p 
in colon cancer cells, we found that miR-142a-5p inhibited the 
proliferation of colon cancer cells, which indicates that the 
effect of miR-142a-5p is contrary to that of PLK1 on colon 
cancer cell proliferation. These results also suggest that miR-
142a-5p acts as a tumor suppressor miRNA in colon cancer 
cells, which provides an experimental basis for clarifying the 
function of miR-142a-5p in colon cancer. 
To verify the binding site between miR-142a-5p and the 
PLK1 gene, we performed dual luciferase reporter gene assays 
and found that the fluorescent value of PLK1 wild-type cells 
transfected with miR-142a-5p mimic decreased, but that of the 
mutant did not change. These results suggest that the 3'-UTR 
of the PLK1 gene is present at the site of miR-142a-5p binding. 
This study also found that the expression level of the PLK1 
gene was significantly decreased after the overexpression of 
miR-142a-5p in two colon cancer cell lines. However, the 
expression level of the PLK1 gene was significantly increased 
when miR-142a-5p was inhibited. In conclusion, this study 
suggests that miR-142a-5p inhibits the proliferation of colon 
cancer cells by downregulating PLK1. 
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